Skip to main content Click to view our accessibility statement

This website is intended for US healthcare professionals only.

INGREZZA® (valbenazine) capsules

One-capsule, once-daily dosing for adults with TD or HD chorea

See dosing for TARDIVE DYSKINESIA (TD)

See dosing for Huntington’s disease (hd) chorea

Only INGREZZA offers a
therapeutic dose from Day 11:

No other VMAT2 inhibitor can offer
the simplicity of INGREZZA1:

Why wait?

Therapeutic dose from Day 1

Why titrate?

No required titration

Why overcomplicate?

Start with INGREZZA

Actor portrayal

GET YOUR PATIENTS STARTED ON INGREZZA RIGHT AWAY

Request samples of INGREZZA® (valbenazine) capsules today to start patients on treatment

CONTACT‍ ‍A REP

The only VMAT2 inhibitor that offers an effective starting dosage you can adjust based on response and tolerability1

DOSING FOR  Tardive dyskinesia (TD)

DOSING FOR
Tardive dyskinesia

DOSING FOR Huntington’s disease (HD) chorea

DOSING FOR
HD chorea

INGREZZA dosing progression for TD INGREZZA dosing progression for TD

Recommended dose is 80 mg.
Adjust based on response and tolerability.

Capsules not actual size

  • Initial dosage of INGREZZA is 40 mg once daily for one week1
  • After the first week, 80 mg is recommended once daily, but 40 mg or 60 mg once daily may be considered based on individual treatment needs, response, and tolerability1

Treat TD while preserving your patient’s antipsychotic regimen

Patients in the clinical trials were allowed to remain on their stable psychiatric treatment regimen1:

85%

took second-generation antipsychotics

27%

took first-generation antipsychotics

In KINECT 3, the most common types of concomitant medications were2,3:

  • Antipsychotics (85.5%)
  • Antidepressants (66.5%)
  • Anticholinergics (37.0%)
  • Antiepileptics (35.2%)
  • Anxiolytics (27.7%)
  • ACE inhibitors (25.1%)

INGREZZA was studied and proven effective in the widest range of patients1

INGREZZA1

AUSTEDO® (deutetrabenazine) and AUSTEDO XR® (deutetrabenazine)4,a

STUDIED?

STUDIED?

Elderly Patients
(≥65 years)

STUDIED?

NO ADJUSTMENT REQUIRED

STUDIED?

Dose selection should be cautious

Insufficient Data; see footnote - asterisk Insufficient Data; see footnote - asterisk

Renal impairment

STUDIED?

NO ADJUSTMENT REQUIRED

STUDIED?

Not Studied Not Studied

Hepatic impairment

STUDIED?

40 mg once daily

MODERATE-SEVERE IMPAIRMENT

STUDIED?

Contraindicated Contraindicated

Concomitant anticholinergics
(eg, benztropine)

STUDIED?

Patients on anticholinergics INCLUDED in pivotal trial​

STUDIED?

Patients on anticholinergics EXCLUDED from pivotal trial​

Dosing considerations do not imply differences in safety, efficacy, or clinical outcomes.

aAUSTEDO® and AUSTEDO XR® are trademarks of Teva Pharmaceutical Industries Ltd.

*See deutetrabenazine prescribing information section 8.5.

†See deutetrabenazine prescribing information section 12.3.

‡See deutetrabenazine prescribing information section 8.6.

INGREZZA Dosing Progression for HD chorea INGREZZA Dosing Progression for HD chorea

Recommended dose is 80 mg.
Adjust based on response and tolerability.

*Increase the dose in 20 mg increments every two weeks to the recommended dose.

Capsules not actual size

The initial dosage for INGREZZA is 40 mg once daily. Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily. A dosage of 40 mg or 60 mg once daily may be considered depending on response and tolerability.1

INGREZZA was studied and proven effective in the widest range of patients1

INGREZZA1

AUSTEDO® (deutetrabenazine) and AUSTEDO XR® (deutetrabenazine)4,a

STUDIED?

STUDIED?

Renal impairment

STUDIED?

NO ADJUSTMENT REQUIRED

STUDIED?

Not Studied Not Studied

Hepatic impairment

STUDIED?

40 mg once daily

MODERATE-SEVERE IMPAIRMENT

STUDIED?

Contraindicated Contraindicated

Elderly Patients
(≥65 years)

No dose adjustment required

Dose selection should be cautious§

Dosing considerations do not imply differences in safety, efficacy, or clinical outcomes.

aAUSTEDO® and AUSTEDO XR® are trademarks of Teva Pharmaceutical Industries Ltd.

†See deutetrabenazine prescribing information section 12.3.

‡See deutetrabenazine prescribing information section 8.6.

§See deutetrabenazine prescribing information section 8.5.

UNIQUELY SELECTIVE PHARMACOLOGY

Only INGREZZA: 100% on-target activity at VMAT25-7,¶

PHARMACOLOGY

EXPLORE FINANCIAL ASSISTANCE OPTIONS

$10 or less out-of-pocket is what most patients pay for INGREZZA8

SAVINGS & SUPPORT

Based on in vitro VMAT2 binding affinity of dihydrotetrabenazine (HTBZ) metabolites and the primary active metabolite of INGREZZA, + α HTBZ. The clinical significance of in vitro data is unknown and is not meant to imply clinical outcomes.

REFERENCES:

  1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
  2. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484.
  3. Data on file. Neurocrine Biosciences, Inc.
  4. Deutetrabenazine [prescribing information]. Parsippany, NJ: Teva Pharmaceutical Industries Ltd.
  5. Brar S, Vijan A, Scott FL, et al. Pharmacokinetic and pharmacologic characterization of the dihydrotetrabenazine isomers of deutetrabenazine and valbenazine. Clin Pharmacol Drug Dev. 2023;12(4):447-456.
  6. Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454-461.
  7. Skor H, Smith EB, Loewen G, O’Brien CF, Grigoriadis DE, Bozigian H. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017;17(3):449-459.
  8. Measured by NDC; data on file as of Q3 2023. Neurocrine Biosciences, Inc.

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.

CONTRAINDICATIONS

INGREZZA and INGREZZA SPRINKLE are contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE.

WARNINGS & PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in patients after taking the first or subsequent doses of INGREZZA. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA or INGREZZA SPRINKLE.

Somnolence and Sedation

INGREZZA and INGREZZA SPRINKLE can cause somnolence and sedation. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA or INGREZZA SPRINKLE.

QT Prolongation

INGREZZA and INGREZZA SPRINKLE may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA and INGREZZA SPRINKLE should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Neuroleptic Malignant Syndrome

A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission, including INGREZZA. The management of NMS should include immediate discontinuation of INGREZZA or INGREZZA SPRINKLE, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems. If treatment with INGREZZA or INGREZZA SPRINKLE is needed after recovery from NMS, patients should be monitored for signs of recurrence.

Parkinsonism

INGREZZA and INGREZZA SPRINKLE may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA or INGREZZA SPRINKLE treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction in patients with tardive dyskinesia (≥5% and twice the rate of placebo) is somnolence.

The most common adverse reactions in patients with chorea associated with Huntington’s disease (≥5% and twice the rate of placebo) are somnolence/lethargy/sedation, urticaria, rash, and insomnia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.

Please see full Prescribing Information, including Boxed Warning.

+Expand-Collapse

Important Safety Information

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.

CONTRAINDICATIONS

INGREZZA and INGREZZA SPRINKLE are contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE.

WARNINGS & PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in patients after taking the first or subsequent doses of INGREZZA. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA or INGREZZA SPRINKLE.

Somnolence and Sedation

INGREZZA and INGREZZA SPRINKLE can cause somnolence and sedation. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA or INGREZZA SPRINKLE.

QT Prolongation

INGREZZA and INGREZZA SPRINKLE may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA and INGREZZA SPRINKLE should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Neuroleptic Malignant Syndrome

A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission, including INGREZZA. The management of NMS should include immediate discontinuation of INGREZZA or INGREZZA SPRINKLE, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems. If treatment with INGREZZA or INGREZZA SPRINKLE is needed after recovery from NMS, patients should be monitored for signs of recurrence.

Parkinsonism

INGREZZA and INGREZZA SPRINKLE may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA or INGREZZA SPRINKLE treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction in patients with tardive dyskinesia (≥5% and twice the rate of placebo) is somnolence.

The most common adverse reactions in patients with chorea associated with Huntington’s disease (≥5% and twice the rate of placebo) are somnolence/lethargy/sedation, urticaria, rash, and insomnia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.

Please see full Prescribing Information, including Boxed Warning.

+

You are now leaving INGREZZAHCP.com

Neurocrine Biosciences, Inc. is not responsible for the content of linked third-party websites. Please be aware that the privacy policies and terms of use on these sites are different from Neurocrine Biosciences, Inc. policies.

STAY HERE LEAVE SITE